Related Experiment Video
Updated: Feb 7, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital
Somi Patro1, Gitanjali Sarangi1, Padma Das2
1Department of Microbiology, S.C.B. Medical College, Cuttack, Odisha, India.
Background:
Ventilator-associated pneumonia (VAP) is the most frequent intensive care unit (ICU)-acquired infection. The etiology of VAP and their antimicrobial susceptibility pattern varies with different patient populations and types of ICUs.
Materials And Methods:
An observational cross-sectional study was performed over a period of 2 years in a tertiary care hospital to determine the various etiological agents causing VAP and to detect the presence of multidrug-resistant (MDR) pathogens in these VAP patients. Combination disk method, Modified Hodge test, ethylenediaminetetraacetic acid disk synergy test, and AmpC disk test were performed for the detection of extended-spectrum beta-lactamase (ESBL), carbapenemases, metallo-beta-lactamases (MBL), and AmpC beta-lactamases, respectively.
Results:
The prevalence of VAP was 35%. Enterobacteriaceae (66.66%) and Staphylococcus aureus (20%) were common in early-onset VAP, while nonfermenters (50%) and Enterobacteriaceae (40.61%) were predominant from late-onset VAP. Nearly 60.87% of the bacterial pathogens were MDR. ESBL was produced by 21.74% of Enterobacteriaceae. AmpC β-lactamase was positive in 35.29% nonfermenters and 26.08% Enterobacteriaceae. MBL was positive in 17.64% nonfermenters and 17.39% Enterobacteriaceae. Among the S. aureus isolates, 75% were cefoxitin resistant. Prior antibiotic therapy (P = 0.001) and hospitalization of 5 days or more (P = 0.001) were independent risk factors for VAP by MDR pathogens. polymyxin B, tigecycline, and vancomycin were the most sensitive drugs for Gram-negative and positive isolates respectively from VAP.
Statistical Analysis:
SPSS for Windows Version SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and Chi-square with Yates correction.
Conclusion:
Late-onset VAP is increasingly associated with MDR pathogens. Treatment with polymyxin B, tigecycline, and vancomycin should be kept as last-line reserve drugs against most of the MDR pathogens.
Insights
Ventilator-associated pneumonia (VAP) is common in ICUs, with late-onset cases increasingly linked to multidrug-resistant (MDR) pathogens. Polymyxin B, tigecycline, and vancomycin show sensitivity against these resistant VAP strains.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Microbiology
Background:
- Ventilator-associated pneumonia (VAP) is a frequent intensive care unit (ICU)-acquired infection.
- The causative agents and antimicrobial resistance patterns of VAP vary significantly across different patient populations and ICU settings.
Purpose of the Study:
- To identify the etiological agents responsible for VAP.
- To determine the prevalence of multidrug-resistant (MDR) pathogens in VAP patients.
- To analyze antimicrobial susceptibility patterns for effective treatment strategies.
Main Methods:
- An observational, cross-sectional study conducted over two years in a tertiary care hospital.
- Utilized combination disk, Modified Hodge, EDTA disk synergy, and AmpC disk tests to detect specific resistance mechanisms (ESBL, carbapenemases, MBL, AmpC).
- Statistical analysis performed using SPSS and Chi-square test with Yates correction.
Main Results:
- VAP prevalence was 35%, with distinct microbial profiles in early-onset (Enterobacteriaceae, Staphylococcus aureus) versus late-onset VAP (nonfermenters, Enterobacteriaceae).
- Nearly 61% of bacterial pathogens isolated were multidrug-resistant (MDR).
- Specific resistance mechanisms like ESBL, AmpC, and MBL were detected in significant proportions of isolates. Prior antibiotic use and prolonged hospitalization (>5 days) were independent risk factors for MDR-VAP.
Conclusions:
- Late-onset VAP is increasingly associated with multidrug-resistant (MDR) pathogens, posing a significant clinical challenge.
- Polymyxin B, tigecycline, and vancomycin demonstrated high sensitivity against Gram-negative and Gram-positive VAP isolates, respectively.
- These agents should be considered crucial last-line treatment options for MDR VAP.
Related Concept Videos
Hospitals-II
Nurses that work in...
Hospitals-I
Tertiary Healthcare System
Mechanical Ventilation II: Invasive Ventilation
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation...
Nomenclature of Secondary and Tertiary Amines

